Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second‐line regimen in the presence of levofloxacin resistance – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 11, 2015-06 ,pp. : 1221-1222

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 11, 2015-06 ,pp. : 1220-1221

John Wiley & Sons Inc

Access to resources Recommend Favorite

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

By Li Yuqin  

Wiener klinische Wochenschrift, Vol. 122, Iss. 13-14, 2010-07 ,pp. : 413-422

Springer Publishing Company

Access to resources Recommend Favorite

Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study

By Zullo Angelo   De Francesco Vincenzo   Hassan Cesare   Panella Carmine   Morini Sergio   Ierardi Enzo  

Therapy, Vol. 3, Iss. 2, 2006-03 ,pp. : 251-254

Future Medicine

Access to resources Recommend Favorite

Editorial: quadruple therapy for H. pylori eradication is better than triple therapy

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 7, 2015-04 ,pp. : 694-695

John Wiley & Sons Inc

Access to resources Recommend Favorite